SUPPLEMENTARY INFORMATION

SOX-5 activates a novel RORyt enhancer to facilitate experimental autoimmune

encephalomyelitis by promoting Th17 cell differentiation

Yi Tian, Chao Han, Zhiyuan Wei, Hui Dong, Xiaohe Shen, Yiqiang Cui, Xiaolan Fu, Zhiqiang Tian,

Shufeng Wang, Jian Zhou, Di Yang, Yi Sun, Jizhao Yuan, Bing Ni, Yuzhang Wu



Supplementary Figure 1. Chromatin signature analysis of a region in human Th17 and Th0 cells similar to mouse RORCE.

Chromatin signature analysis of a region similar to mouse RORCE (indicated by the red box) including H3K27me3, H3K9me3, H3K27Ac, H3K36me3, H3K4me1 and H3K4me3 in human Th17 and Th0 cells with the Roadmap Epigenomics Project database (http://egg2.wustl.edu/roadmap/web_portal/).



Supplementary Figure 2. Validation of active enhancer-associated epigenetic markers in RORCE in Th17 cells.

a. Based on the median size of common enhancers, RORCE was subdivided into three consecutive fragments: RORCE1 (chr3: 94,169,746-94,170,945), RORCE2 (chr3: 94,170,946-94,172,113), and RORCE3 (chr3: 94,172,215-94,173,149). Red boxes represent the targeted regions detected by ChIP-qPCR with 6 corresponding primer pairs (A-F). b. Sorting of Th17 and non-Th17 cells from IL-17A-EGFP reporter mice was performed by FACS. Splenic CD4⁺ T cells were sorted into CD4⁺GFP⁺ Th17 and CD4⁺GFP⁻ non-Th17 cells, and the purities of sorted cells were further confirmed with an anti-ROR γ t mAb before use. c-e. ChIP-qPCR analysis for H3K4me1 (c), H3K27Ac (d) and H3Ac (e) in the RORCE region of the sorted cells is shown. Mean ± SEM are shown, n=5 independent experiments, unpaired two-tailed Student's t-test (c-e). Experimental mice were between 8 and 12 weeks of age, with no preference to gender and were maintained on a C57BL/6 background. Source data are provided as a Source Data file.



Supplementary Figure 3. Gating strategies used for cell sorting and frequency analysis.

a. Gating strategy to sort Th17 (CD4⁺GFP⁺) and non-Th17 cells (CD4⁺GFP⁻) from IL-17A-EGFP reporter mice presented on supplementary Figure 2. b. Gating strategy to determine the percentage of CD4⁺IL-17A⁺Th17 cells in splenic CD4⁺ T cells presented on Figure 2f and the same strategy was used in Figure 2c, supplementary Figure 4b, supplementary Figure 4d, Figure 7b, Figure 7d. c. Gating strategy to determine the percentage of ROR γ t⁺ Th17 in CD4⁺CD45⁺ Lin⁺ lymphocyte population from LP of small intestine presented on Figure 2h and the same strategy was used in Figure 2l, Figure 7f, Figure 7h. d. Gating strategy to determine the percentage of CD127⁺ ROR γ t⁺ ILC3 cells in the CD45⁺ Lin⁻ lymphocyte population of the lamina propria presented on Figure 2p. e. Gating strategy to determine the percentage of CD4⁺ROR γ t⁺ Th17 cells that differentiated from Naïve CD4⁺ T cells presented on Figure 3a and the same strategy was used in Figure 3d, Figure 3i, Figure 3m, Figure 7i, Figure 7j. f. Gating strategy to analyze the percentage of CD4⁺IL-17A⁺Th17 cells in CD45⁺CD4⁺ T cells of the spinal cord of indicated mice presented on Figure 4c and the same strategy was used in Figure 4d, Figure 4e, Figure 8c.



Supplementary Figure 4. Sequencing results of top 10 potential off targets of upstream sgRNAs or downstream sgRNAs used in RORCE2^{-/-}mice

Top 10 potential off targets of upstream sgRNAs or downstream sgRNAs used in RORCE2^{-/-}mice were amplified by PCR with genomic DNA of RORCE2^{-/-}mice and then PCR products were sequenced. PCR primers used for this assay are listed in Supplementary **Table 1**.



Supplementary Figure 5. RORCE2 deficiency has no effects on Th1 or Th2 cells *in vivo*.

a-c. Relative expression of *Tbx21* gene (a) and frequency of Th1 cells stained with an anti-TBX21 or anti-IFN γ mAb in RORCE2^{-/-} and WT mice (b and c). d-f. Relative expression of *Gata3* gene (d) and frequency of Th2 cells stained with an anti-GATA3 or anti-IL-4 mAb in RORCE2^{-/-} and WT mice (e and f). Mean ± SEM are shown, n=5 independent experiments, unpaired two-tailed Student's t-test (a, c, e, f). Experimental mice were between 8 and 12 weeks of age, with no preference to gender and were maintained on a C57BL/6 background. Source data are provided as a Source Data file.



Supplementary Figure 6. The mRNA expression of *RORyt* in EL4 cells.

a. Relative mRNA expression levels of $ROR\gamma t$ (*Rorc*) gene in PI-stimulated EL4 cells at indicated time points were measured by RT-qPCR. b. Relative mRNA expression levels of $ROR\gamma t$ (*Rorc*) gene in EL4 and B16 cells after PI stimulation for 4 h were measured by RT-qPCR. Mean ± SEM are shown, n=4 or 5 (a with n=4 and b with n=5) independent experiments, unpaired two-tailed Student's t-test (a, b). Source data are provided as a Source Data file.



Supplementary Figure 7. Relative mRNA expression of the Sox5 gene in Th17 cells.

Relative mRNA expression of *Sox5* gene in Th17-polarized and PI-stimulatedEL4 cells compared with that in naïve cells and PI-stimulated B16 cells, respectively. Th17 D represents Th17 differentiation under Th17 polarization conditions. Mean ± SEM are shown, n=5 independent experiments, unpaired two-tailed Student's t-test. Experimental mice were between 8 and 12 weeks of age, with no preference to gender and were maintained on a C57BL/6 background. Source data are provided as a Source Data file.



Supplementary Figure 8. The proposed model for RORCE2-mediated regulation of RORyt expression in Th17 cells.

Previous studies have indicated that SOX-5, as a downstream target of STAT3, and c-Maf cooperatively induce the induction of ROR γ t and differentiation of Th17 cells via binding to the ROR γ t promoter. In this study, we uncovered that *ROR* γ t gene expression in Th17 cells was also mediated by a novel enhancer, named RORCE2. SOX-5 was required for chromatin looping between RORCE2 and ROR γ t promoter and for the binding of STAT3 to RORCE2, which is crucial for ROR γ t expression, Th17 cell differentiation and Th17-related diseases and most likely functions together with other TFs.

Target Primer name Primer sequence (5' to 3') #1 potential off target of upstream sgRNAs TCTCCCAGAGCACCCGAGTT SgRNAs-up-1 F SgRNAs-up-1_R GTCTGTGTCAGAACGGGAGTG #2 potential off target of upstream sgRNAs SgRNAs-up-2 F AGCCTCCCCAATGAAACGCAATG SgRNAs-up-2 R CAATACACCTCTGAATGTCTCCCG CAGTTCCCAGCATCCATACAGG #3 potential off target of upstream sgRNAs SgRNAs-up-3 F SgRNAs-up-3 R GGCCATCCCTACCTTCTGGTAA #4 potential off target of upstream sgRNAs SgRNAs-up-4_F GACTCAGTTTCAAACCTGGGCC GTTGGACGTACCACAGCTTTCATC SgRNAs-up-4 R #5 potential off target of upstream sgRNAs SgRNAs-up-5 F GGTTAGCACCGTTTAACCAGTGAG SgRNAs-up-5 R CTCCTAGACTCCTCCTACCAC CCTCCTCGTCACACTAAACTCC #6 potential off target of upstream sgRNAs SgRNAs-up-6 F GAGCAGAATAGACACAAGCCCTCC SgRNAs-up-6_R #7 potential off target of upstream sgRNAs SgRNAs-up-7 F CTGTAGGTGCACTTATCCTTCAGC SgRNAs-up-7_R CAGTACCTCAACTCACCACCC #8 potential off target of upstream sgRNAs SgRNAs-up-8 F TCTGGTCAGGATAAGCACTGAGC SgRNAs-up-8 R GCTACGTGCTAAGGACCTACTATG #9 potential off target of upstream sgRNAs SgRNAs-up-9_F CCAAGGACCAAGGCAAGAGAAG CCCTAGCTTCCTCCTACCAG SgRNAs-up-9_R #10 potential off target of upstream sgRNAs SgRNAs-up-10 F GCAGAATGAGCCAACTATGCCC SgRNAs-up-10 R CCACAGTCCAGAGCAGAAGAAG #1 potential off target of downstream ATTCCCTCACAAGCTGCTGAATCC SgRNAs-down-1 F sgRNAs SgRNAs-down-1 R AACCTCTCACCCTGTGTGACATAG TCCAGTGCTTTCTTCAGGTAGCTC #2 potential off target of downstream SgRNAs-down-2_F SgRNAs-down-2 R AGCCTACTGTGCGAATGGTCTC sgRNAs CTGGTCCTAGTTCCCACCTC #3 potential off target of downstream SgRNAs-down-3 F sgRNAs SgRNAs-down-3 R CACCAACCCTGGGTTGAAATCC #4 potential off target of downstream SgRNAs-down-4 F AAAGCTGATCTTTCGGATCCTGGG sgRNAs SgRNAs-down-4_R CCCATCCAAGTCTTCTCTCAGTG #5 potential off target of downstream SgRNAs-down-5 F GGTGATGAGTAAGGACTCTTCAGC CTCGGTGCTGGGATTAAAGGC sgRNAs SgRNAs-down-5_R #6 potential off target of downstream SgRNAs-down-6 F GGCACATCAGGATCACTCCTTC sgRNAs CTGGGTTTGGTCTATGGCTATCTG SgRNAs-down-6 R SgRNAs-down-7_F ACCTGTTCCTCCCCCTATTTCAGA #7 potential off target of downstream SgRNAs-down-7 R GTCTCTCTGGGTGAGAGTGAAAG sgRNAs #8 potential off target of downstream SgRNAs-down-8_F GAAAAGAAGGGATCAGGGAAGGG GGAGATTGTAGTGCAGCCAACTTC sgRNAs SgRNAs-down-8 R SgRNAs-down-9 F GGGCTATGGGGTTTTGGATCTC #9 potential off target of downstream sgRNAs SgRNAs-down-9 R GACACAGATACACTGAGACAGTGC

SgRNAs-down-10_F

SgRNAs-down-10 R

GTTCAGTGTCCAGTTTAAGGCTCC

AGTAGCCCCCTGTAGCTTCC

#10 potential off target of downstream

sgRNAs

Supplementary Table 1. Primers used for PCR of top 10 potential off targets of upstream sgRNA or downstream sgRNA used in RORCE2^{-/-}mice.

| Gene name | Primer name | Primer sequence (5' to 3') |
|-----------|-------------|--|
| RORCE1 | RORCE1_F | 5-TACGACGCGTTCAGTCTTCCACATCAAGTAATTGCAAT-3 |
| | RORCE1_R | 5-CTGAAGATCTCTAATGTTTGAAGCTGTCCATCCTACC-3 |
| RORCE2 | RORCE2_F | 5-TACGACGCGT TTCCTCCTGGCAACTGCCTCTAAG-3 |
| | RORCE2_R | 5-CTGAAGATCTACAAGGAAGACTTTAACAGTGTGGTTTG-3 |
| RORCE3 | RORCE3_F | 5-TACGACGCGTGAACTCCTCCTGCTCTTCCAGCCTCT-3 |
| | RORCE3_R | 5-CTGAAGATCTAGTTACAGAGACAAAATTTGGAGCTGTG-3 |
| RORCE1/2 | RORCE1/2_F | 5-TACGACGCGTTCAGTCTTCCACATCAAGTAATTGCAAT-3 |
| | RORCE1/2_R | 5-CTGAAGATCTACAAGGAAGACTTTAACAGTGTGGTTTG-3 |
| RORCE2/3 | RORCE2/3_F | 5-TACGACGCGT TTCCTCCTGGCAACTGCCTCTAAG-3 |
| | RORCE2/3_R | 5-CTGAAGATCTAGTTACAGAGACAAAATTTGGAGCTGTG-3 |
| RORCEf | RORCEf_F | 5-TACGACGCGTTCAGTCTTCCACATCAAGTAATTGCAAT-3 |
| | RORCEf_R | 5-CTGAAGATCTAGTTACAGAGACAAAATTTGGAGCTGTG-3 |

Supplementary Table 2. Primers used for reporter construct cloning.

| Gene name | Primer name | Primer sequence (5' to 3') |
|-----------|-------------|----------------------------|
| Primer A | Primer A_F | 5-CCACACAGTGCCCTTTAACC-3 |
| | Primer A_R | 5-ATGTCCCAGATCCCAGTCC-3 |
| Primer B | Primer B _F | 5-CAGCCAGAAGATGAAGGTG-3 |
| | Primer B _R | 5-GCTAAGAGGAAGGAAGGAAGTG-3 |
| Primer C | Primer C_F | 5-AACCTGGCACTTCGCACTTA-3 |
| | Primer C_R | 5-GCATTGCTCACTAGGGATTG-3 |
| Primer D | Primer D_F | 5-ATTGGCTTTGGCTGTGAGG-3 |
| | Primer D_R | 5-CTACTGTGCTAATGGCGGT-3 |
| Primer E | Primer E_F | 5-CCACGTTATGAGGTGCTGTAGG-3 |
| | Primer E_R | 5-TGGAGGAGTAGCGGGAAAGA-3 |
| Primer F | Primer F_F | 5-CGAGTTGAAGTCTCCGTAAGC-3 |
| | Primer F_R | 5-TCCCAAGGCAGCAGGTAA-3 |
| SOX-5-BS | SOX-5 BS_F | 5-TCCACTATGTTCCCACCAC-3 |
| | SOX-5 BS_R | 5-GTCAGCACGGAGGATTGTT-3 |
| RORyt p | RORyt_F | 5-TTGACAGTCCACAGGGTCTC-3 |
| | RORyt_R | 5-GCCCTCTTCACCAAGTGACA-3 |
| STAT3-BS | STAT3 BS_F | 5-GGGTAGGATGGACAGCTTCA-3 |
| | STAT3 BS_R | 5-AACAACTGTACACTCACCTTAG-3 |

Supplementary Table 3. Primers used for ChIP-qPCR.

| Gene name | Primer name | Primer sequence (5' to 3') |
|-----------|-------------|------------------------------|
| RORγt | RORyt_F | 5-CGAGATGCTGTCAAGTTTGG-3 |
| | RORyt_R | 5-CACTTGTTCCTGTTGCTGCT-3 |
| IL-17A | IL-17A _F | 5-TCCAGAAGGCCCTCAGACTA-3 |
| | IL-17A_R | 5-TCAGGACCAGGATCTCTTGC-3 |
| Tbx21 | Tbx21_F | 5-GCCAGGGAACCGGTTATATG-3 |
| | Tbx21_R | 5-GACGATCATCTGGGTCACAT-3 |
| Gata3 | Gata3_F | 5-AAGCTCAGTATCCGCTGACG-3 |
| | Gata3_R | 5-GTTTCCGTAGTAGGACGGGAC-3 |
| Sox5 | Sox5_F | 5-ACATCGGGAAGTAGGAGAGACTGA-3 |
| | Sox5_R | 5-TACCTCTCCATCTGTCTCCCCATA-3 |
| Stat3 | Stat3_F | 5-CTAACATTCTGGGCACGAAC-3 |
| | Stat3-R | 5- AAACTGGCAAGGAGTGGGTC-3 |
| GAPDH | GAPDH_F | 5-ACAGCCGCATCTTCTTGTGCAGTG-3 |
| | GAPDH_R | 5-GGCCTTGACTGTGCCGTTGAATTT-3 |

Supplementary Table 4. Primers used for RT-qPCR.

| Gene name | Primer name | Primer sequence (5' to 3') |
|-----------|-------------|----------------------------|
| GAPDH | GAPDH_F_3C | 5-TACCTGATGAACCTAAGC-3 |
| | GAPDH_R_3C | 5-GTGAAAGGGGCAGTGTCT-3 |
| NCS | NCS | 5-GTCTCAAAATAACACCCCAC-3 |
| TS1 | TS1 | 5-ATCAAGAGAATCCCCCACT-3 |
| TS2 | TS2 | 5-CACTTCCTCCTTCCTCTT-3 |
| TS3 | TS3 | 5-TCCTGACAACTGCCTCTAA-3 |
| TS4 | TS4 | 5-CTTCGCCCTAAGACAGATA-3 |
| TS5 | TS5 | 5-AGGGAGGCAAAATTACAG-3 |
| TS6 | TS6 | 5-GTTCAGTCACATTCCCAC-3 |
| TS7 | TS7 | 5-TACCGCCATTAGCACAGT-3 |
| TS8 | TS8 | 5-AGAGGGTCCAGTGAAAGAT-3 |
| AS | AS | 5-TTCCAAAACCACAGCTAC-3 |

Supplementary Table 5. Primers used for 3C-qPCR and ChIP-loop assays.